Public health issues arising from sale of illegal and potentially unsafe 'tanning chemicals'

Pigment Cell and Melanoma Research

Volumn 22, Issue 5, 2009, Pages 648-

  Del Marmol, Veronique ^a   Luger, Thomas ^b   Neumann, Norbert J ^c   Ortonne, Jean Paul ^d  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMELANOTIDE; ALPHA INTERMEDIN; ALPHA INTERMEDIN DERIVATIVE; GENERIC DRUG; MELANOTAN II; UNCLASSIFIED DRUG;

CONGENITAL ERYTHROPOIETIC PORPHYRIA; DRUG MARKETING; DRUG PURITY; DRUG SAFETY; DRUG SELF ADMINISTRATION; HUMAN; LETTER; PUBLIC HEALTH; SKIN PIGMENTATION; SKIN TANNING;

ALPHA-MSH; BEAUTY CULTURE; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; PUBLIC HEALTH; SKIN; SKIN PIGMENTATION; ULTRAVIOLET RAYS;

EID: 69449099367     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2009.00594.x     Document Type: Letter

References (3)

1. Barnetson, R., Ooi, T., Zhuang, L., Halliday, G., Reid, C., Walker, P., Humphrey, S. Kleinig, M. (2006). Nle-D-Phe7-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned caucasian volunteers. Journal Investigative dermatology 126, 1869 1878.
2. Harms, J., Lautenschlager, S., Minder, C.E. Minder, E. (2009). An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N. Engl. J. Med. 360, 306 307.
3. Tran, T.-N., Shulman, J. Fisher, D. (2008). UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell Melanoma Res 21, 509 516.